| pubmed-article:18037292 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18037292 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:18037292 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:18037292 | lifeskim:mentions | umls-concept:C0278488 | lld:lifeskim |
| pubmed-article:18037292 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:18037292 | lifeskim:mentions | umls-concept:C1552617 | lld:lifeskim |
| pubmed-article:18037292 | lifeskim:mentions | umls-concept:C0282443 | lld:lifeskim |
| pubmed-article:18037292 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:18037292 | pubmed:dateCreated | 2008-6-2 | lld:pubmed |
| pubmed-article:18037292 | pubmed:abstractText | Many active cytotoxic drugs, given according to a number of different regimens are approved for the treatment of metastatic breast cancer patients. However, these therapies have not changed the outcome of patients affected by this malignancy. As a consequence, the balance between chemotherapy-induced side effects and relief of cancer-related symptoms must be carefully considered in this setting. Gemcitabine is an antimetabolite that is incorporated as a triphosphate into DNA. As a single agent, it yields responses rates ranging from 14% to 37% in chemotherapy-naïve patients and from 12% to 30% in patients previously treated with anthracyclines and/or taxanes. In combination with paclitaxel, it produces a significantly higher response rate (41.4% vs. 26.2%), longer time to progression (6.1 vs. 4 months) and significantly higher overall survival (18.6 vs. 15.8 months) than paclitaxel alone. In addition, a phase III study revealed that gemcitabine plus docetaxel is as effective as capecitabine plus docetaxel, but causes significantly less non-haematologic toxicity. Lastly, in another phase III trial, progression free survival was significantly longer with the combination of gemcitabine plus vinorelbine than with vinorelbine alone (6 vs. 4 months), but without a significant difference in overall survival; the incidence of haematologic toxicity was higher in the group treated with combined therapy. Novel gemcitabine combinations are being investigated in phase II studies. | lld:pubmed |
| pubmed-article:18037292 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18037292 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18037292 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18037292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18037292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18037292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18037292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18037292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18037292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18037292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18037292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18037292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18037292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18037292 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18037292 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18037292 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:18037292 | pubmed:issn | 0960-9776 | lld:pubmed |
| pubmed-article:18037292 | pubmed:author | pubmed-author:NumicoGianmau... | lld:pubmed |
| pubmed-article:18037292 | pubmed:author | pubmed-author:SilvestrisNic... | lld:pubmed |
| pubmed-article:18037292 | pubmed:author | pubmed-author:LorussoVitoV | lld:pubmed |
| pubmed-article:18037292 | pubmed:author | pubmed-author:PezzellaGiuse... | lld:pubmed |
| pubmed-article:18037292 | pubmed:author | pubmed-author:OrlandoLauraL | lld:pubmed |
| pubmed-article:18037292 | pubmed:author | pubmed-author:CinieriSaveri... | lld:pubmed |
| pubmed-article:18037292 | pubmed:author | pubmed-author:La... | lld:pubmed |
| pubmed-article:18037292 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18037292 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:18037292 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18037292 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18037292 | pubmed:pagination | 220-6 | lld:pubmed |
| pubmed-article:18037292 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:18037292 | pubmed:meshHeading | pubmed-meshheading:18037292... | lld:pubmed |
| pubmed-article:18037292 | pubmed:meshHeading | pubmed-meshheading:18037292... | lld:pubmed |
| pubmed-article:18037292 | pubmed:meshHeading | pubmed-meshheading:18037292... | lld:pubmed |
| pubmed-article:18037292 | pubmed:meshHeading | pubmed-meshheading:18037292... | lld:pubmed |
| pubmed-article:18037292 | pubmed:meshHeading | pubmed-meshheading:18037292... | lld:pubmed |
| pubmed-article:18037292 | pubmed:meshHeading | pubmed-meshheading:18037292... | lld:pubmed |
| pubmed-article:18037292 | pubmed:meshHeading | pubmed-meshheading:18037292... | lld:pubmed |
| pubmed-article:18037292 | pubmed:meshHeading | pubmed-meshheading:18037292... | lld:pubmed |
| pubmed-article:18037292 | pubmed:meshHeading | pubmed-meshheading:18037292... | lld:pubmed |
| pubmed-article:18037292 | pubmed:meshHeading | pubmed-meshheading:18037292... | lld:pubmed |
| pubmed-article:18037292 | pubmed:meshHeading | pubmed-meshheading:18037292... | lld:pubmed |
| pubmed-article:18037292 | pubmed:meshHeading | pubmed-meshheading:18037292... | lld:pubmed |
| pubmed-article:18037292 | pubmed:meshHeading | pubmed-meshheading:18037292... | lld:pubmed |
| pubmed-article:18037292 | pubmed:meshHeading | pubmed-meshheading:18037292... | lld:pubmed |
| pubmed-article:18037292 | pubmed:meshHeading | pubmed-meshheading:18037292... | lld:pubmed |
| pubmed-article:18037292 | pubmed:meshHeading | pubmed-meshheading:18037292... | lld:pubmed |
| pubmed-article:18037292 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18037292 | pubmed:articleTitle | Role of gemcitabine in metastatic breast cancer patients: a short review. | lld:pubmed |
| pubmed-article:18037292 | pubmed:affiliation | Operative Unit of Medical Oncology, Moscati General Hospital, Via per Martina Franca, 74100 Taranto, Italy. nicolasilvestris@virgilio.it | lld:pubmed |
| pubmed-article:18037292 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18037292 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18037292 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18037292 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18037292 | lld:pubmed |
